Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype
2017 · Scientific Reports · 171 citations
https://doi.org/10.1038/srep39011
F
Fangfang Lai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
2.2K
Citations
24
h-index
46
i10-index
Fangfang Lai is an academic researcher from Academy of Medical Sciences. The author has contributed to research in topics: Ion Transport and Channel Regulation & Sphingolipid Metabolism and Signaling & Peptidase Inhibition and Analysis. The author has an h-index of 24, co-authored 79 publications.
ORCID: 0000-0003-1696-6208Papers by this author
worksRutaecarpine suppresses atherosclerosis in ApoE−/− mice through upregulating ABCA1 and SR-BI within RCT
2014 · Journal of Lipid Research · 66 citations
https://doi.org/10.1194/jlr.m044198
Associations between serum total bilirubin, obesity and type 2 diabetes
2021 · Diabetology & Metabolic Syndrome · 28 citations
https://doi.org/10.1186/s13098-021-00762-0
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
2022 · Acta Pharmaceutica Sinica B · 26 citations
https://doi.org/10.1016/j.apsb.2022.02.031
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
2023 · Acta Pharmaceutica Sinica B · 0 citations
https://doi.org/10.1016/j.apsb.2023.05.003
MSR106 Impact of Censoring Rules on Q-Twist Analysis and Challenges in Oncology Research: A Simulation Study
2024 · Value in Health · 0 citations
https://doi.org/10.1016/j.jval.2024.10.2340
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat